#1 Clinical Trials Search in Europe

Tetrahydrouridine

Tetrahydrouridine (THU) is being studied in various clinical trials as a supportive drug to enhance the effectiveness of other cancer treatments. THU is often combined with drugs like decitabine or cytochlor to improve their absorption and distribution in the body. These trials aim to explore THU’s potential in treating different types of cancer, including lung cancer, blood disorders, and head and neck cancers.

Table of Contents

What is Tetrahydrouridine (THU)?

Tetrahydrouridine, often abbreviated as THU, is an experimental drug being studied for its potential in cancer treatment. It’s important to note that THU is not a standalone cancer treatment. Instead, it’s used in combination with other drugs to enhance their effectiveness[1][2].

THU is also known by its other name, H4U[3]. This drug is not yet approved by the Food and Drug Administration (FDA) for general use, but it has been extensively used in clinical trials, including several cancer trials[4].

How THU Works

THU works in a unique way. It’s not a direct cancer-fighting drug, but rather a helper drug that makes other cancer treatments more effective. Here’s how it works:

  • Enzyme inhibition: THU blocks an enzyme called cytidine deaminase. This enzyme is responsible for breaking down certain cancer drugs in the body[1].
  • Prolonging drug action: By blocking the enzyme that breaks down cancer drugs, THU helps these drugs stay in the body longer. This means the cancer cells are exposed to the treatment for a longer time, potentially making the treatment more effective[4].
  • Improving drug distribution: THU can help cancer drugs reach solid tissues more effectively. This is particularly important for treating solid tumors[4].

Conditions Treated with THU

THU is being studied in combination with other drugs for the treatment of various types of cancer, including:

  • Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer[4].
  • Pancreatic cancer: THU is being studied in combination with another drug called decitabine for treating advanced pancreatic cancer[1].
  • Lymphoid malignancies: These are cancers that affect certain types of white blood cells[5].
  • Esophageal cancer: Cancer of the food pipe or esophagus[4].
  • Sickle cell disease: While not a cancer, THU is also being studied for its potential in treating this blood disorder[6].

How THU is Administered

The way THU is given to patients can vary depending on the specific study or treatment plan. Here are some common methods:

  • Oral administration: In some studies, THU is given as capsules that patients take by mouth[1][2].
  • Intravenous (IV) administration: In other studies, THU is given through a vein[3].
  • Dosage: The dose of THU can vary. In some studies, it’s based on the patient’s weight. For example, one study used 10 mg/kg of THU[4].
  • Timing: THU is often given before the main cancer drug. For instance, it might be given 60 minutes before another drug called decitabine[1].

Current Clinical Trials

THU is currently being studied in several clinical trials. These trials are research studies that help doctors understand how well new treatments work. Some notable trials include:

  • Pancreatic cancer study: A trial combining THU with decitabine for advanced pancreatic cancer[1].
  • Lung cancer study: A trial using THU with decitabine and another drug called pembrolizumab for non-small cell lung cancer[4].
  • Lymphoma study: A trial using THU with decitabine for various types of lymphoma[5].
  • Sickle cell disease study: A trial using THU with decitabine to potentially increase fetal hemoglobin levels in patients with sickle cell disease[6].

Potential Side Effects

As THU is still being studied, all of its potential side effects are not yet fully known. However, researchers are carefully monitoring patients in clinical trials for any adverse effects. Some studies have reported that the combination of THU with other drugs has been generally well-tolerated[1][2].

It’s important to note that in clinical trials, doctors closely monitor patients for any side effects. If you’re considering participating in a clinical trial involving THU, the research team will provide detailed information about potential risks and benefits.

Aspect Details
Primary Use Enhancing effectiveness of other cancer drugs (e.g., decitabine, cytochlor)
Mechanism of Action Inhibits cytidine deaminase enzyme, increasing exposure time of cancer cells to primary drugs
Administration Usually oral, often given before primary drug
Cancer Types Studied Non-small cell lung cancer, pancreatic cancer, lymphoid malignancies, sickle cell disease, head and neck cancers
Combination Therapies Often combined with decitabine, cytochlor, or radiation therapy
Key Benefits Improves bioavailability and effectiveness of other cancer drugs, especially in solid tumors
Research Focus Determining optimal dosing, safety profile, and efficacy in various cancer types
Trial Phases Primarily Phase I and II studies

FAQ

  • What is tetrahydrouridine (THU) and how does it work? Tetrahydrouridine (THU) is a drug that works by blocking an enzyme called cytidine deaminase. This enzyme normally breaks down certain cancer drugs. By inhibiting this enzyme, THU helps increase the time that cancer cells are exposed to the main cancer-fighting drugs, potentially making the treatment more effective.
  • Which types of cancer are being studied with THU in clinical trials? Clinical trials are exploring the use of THU in various types of cancer, including non-small cell lung cancer, pancreatic cancer, lymphoid malignancies, sickle cell disease, and head and neck cancers. It's being tested in combination with other drugs to treat both solid tumors and blood disorders.
  • How is THU usually administered in these clinical trials? In most clinical trials, THU is administered orally in capsule form. It's often given before another drug, such as decitabine, with a specific time interval between the two. The dosage and frequency can vary depending on the specific trial and the patient's weight.
  • What are some potential benefits of using THU in cancer treatment? The potential benefits of using THU include improving the bioavailability and effectiveness of other cancer drugs, especially in solid tumors. It may help increase the exposure of cancer cells to these drugs, potentially leading to better treatment outcomes. THU may also allow for lower doses of certain cancer drugs while maintaining their effectiveness.
  • Are there any known side effects of THU? While specific side effects of THU alone are not detailed in these trial descriptions, the combination of THU with other drugs is being closely monitored for toxicities. The trials are designed to determine the safety profile and maximum tolerated dose of THU when used in combination with other cancer treatments.

Ongoing Clinical Trials on Tetrahydrouridine

  • Study on the Effectiveness of Decitabine and Tetrahydrouridine in Patients with Sickle Cell Disease Not Eligible for Hydroxyurea Treatment

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Greece Italy Spain

Glossary

  • Tetrahydrouridine (THU): A drug that inhibits the enzyme cytidine deaminase, which normally breaks down certain cancer drugs. THU is used to enhance the effectiveness of other cancer treatments.
  • Decitabine (DAC): A cancer drug that works by depleting an enzyme called DNA methyltransferase 1 (DNMT1). It's often used in combination with THU in clinical trials.
  • Cytochlor: An investigational drug being studied as a radiosensitizer in cancer treatment. It's often used in combination with THU in clinical trials.
  • Bioavailability: The extent and rate at which a drug enters systemic circulation, thereby accessing the site of action.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that does not cause unacceptable side effects. It's often determined in phase I clinical trials.
  • Dose-Limiting Toxicity (DLT): Side effects of a treatment that are severe enough to prevent an increase in dose or require a dose reduction.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Epigenetic therapy: Treatment that targets the epigenome, which controls how genes are expressed without changing the DNA sequence.
  • Immune checkpoint inhibitors: A type of cancer treatment that blocks certain proteins made by immune system cells, such as T cells, and some cancer cells.

References

  1. https://clinicaltrials.gov/study/NCT02847000
  2. https://clinicaltrials.gov/study/NCT05816356
  3. https://clinicaltrials.gov/study/NCT00521183
  4. https://clinicaltrials.gov/study/NCT02664181
  5. https://clinicaltrials.gov/study/NCT02846935
  6. https://clinicaltrials.gov/study/NCT01685515